Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6006753A · kind A · utility
222Cited by
4References
13Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 21, 1997 |
| Grant date | Dec 28, 1999 |
| Priority date | — |
| Expiry date | Aug 21, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/605
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a method of attenuating post-surgical catabolic changes and hormonal responses to stress. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.